Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C

Canadian Journal of Gastroenterology

Volumn 20, Issue 9, 2006, Pages 589-592

  Nudo, C G ^a   Wong, P ^a   Hilzenrat, N ^a   Deschênes, Marc ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cytopenia; Hepatitis C; Pegylated interferon therapy; Ribavirin therapy

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ATTRIBUTABLE RISK; BLOOD CELL COUNT; CONTROLLED STUDY; CYTOPENIA; DEPRESSION; DERMATITIS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INSOMNIA; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PRURITUS; RIGOR; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 33750193897     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/357259     Document Type: Article

References (20)

1. Hepatitis C - Global prevalence (update). Wkly Epidemiol Rec 1999;74:425-7.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
3. Ferenci P, Brunner H, Nachbaur K, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34:1006-11.
4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
5. Poynard T, Marcellin P, Lee S, et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
6. Management of Hepatitis C. NIH Consensus Statement 1997;15:1-41.
7. Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36(Suppl 1):226-36.
8. Friedel DM, Ozick L. Hepatitis C in the Elderly. Clin Geriatr 1999;7.
9. Van-Thiel DH, Friedlander L, Caraceni P, Molley PJ, Kania RJ. Treatment of hepatitis C virus in elderly persons with interferon alpha. J Gerontol Med Sci 1995;50:330-3.
10. Bresci G, Del Corso L, Romanelli AM, Giuliano G, Pentimone F. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993;41:857-62.
11. Horiike N, Masumoto T, Nakamishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-9.
12. Alessi N, Freni MA, Spadaro A, et al. Efficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis C. Infez Med 2003;11:208-12.
13. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 2,410 patients 65 years or older a severe and neglected curable disease. Hepatology 2003;38(Suppl 1):549A. (Abst)
14. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002;97:149-55.
15. Common Toxicity Criteria Version 2.0. Bethesda: National Cancer Institute, 1999.
16. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
17. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
18. Okafor O, Ojo S. A comparative analysis of six current histological classification schemes and scoring systems used in chronic hepatitis reporting. Rev Esp Patol 2004;37:269-77.
19. Fried MW, Shifman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
20. McHutchison JG, Poynard T, Harvey J, Garaud JJ, Albrecht JK. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin. Hepatology 2000;32:223A. (Abst)